COVID-19
The EUA was granted base on interim data from the Phase III COMET-ICE trial in high-risk adult outpatients.
Drug companies have been suggesting that booster shots will be needed. However, it is up to the CDC’s recommendation if booster shots are necessary.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
Ocugen submitted a “Master File” to the U.S. FDA for COVAXIN, the vaccine that has already received authorization in India for people ages 12 and above.
The White House has also called for an independent investigation and more information from China about the pandemic’s origins.
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
The disclosure comes the day before the WHO is expected to plan for the next phase of investigations into the origins of COVID-19.
It was another busy week for clinical trial announcement. Here’s a look.
Researchers at John Hopkins made their preliminary conclusions that the vaccines produced by Pfizer-BioNTech and Moderna did not cause the hearing loss.
PRESS RELEASES